Applied Biosystems Completes Equity Investment in VisiGen
News Dec 12, 2005
Concurrent with its investment, Applied Biosystems also entered into a scientific collaboration agreement with VisiGen.
The VisiGen investment is part of Applied Biosystems’ strategy of maintaining its position in DNA sequencing by complementing its internal investments in new and existing sequencing technologies with promising next-generation approaches.
VisiGen’s technological approach to DNA sequencing is based on the ability to analyze a single molecule of DNA in real-time.
Avacta Group plc announces successful outcome of “Gene Delivery” collaboration with FIT BiotechNews
Sustained production of Affimer drugs by muscle tissue in vivo could lead to major patient and commercial benefits.READ MORE
SCRaMbLE Speeds Up Yeast EvolutionNews
Scientists have created a new way of speeding up the genome evolution of baker’s yeast Saccharomyces cerevisiae. This is to develop a synthetic yeast strain that can be transformed on demand, making it industrial applications such as the mass production of advanced medicines to treat illnesses such as malaria and tuberculosis (TB).READ MORE
Artificial Cellular Compartments BuiltNews
How to install new capabilities in cells without interfering with their metabolic processes? A team from the Technical University of Munich (TUM) and the Helmholtz Zentrum München have altered mammalian cells in such a way that they formed artificial compartments in which sequestered reactions could take place, allowing the detection of cells deep in the tissue and also their manipulation with magnetic fields.READ MORE